Cima Labs completes manufacturing facility for OraSolv(R) products; CIMA also names Jack Khattar as vice president of Business Development.MINNEAPOLIS--(BUSINESS WIRE)--Feb. 14, 1995--CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq: CIMA) today announced that it has completed the manufacturing facility for products which utilize its OraSolv(R) technology. To complement its corporate infrastructure, the Company also announced the appointment of Jack Khattar as Vice President of Business Development, reporting to CIMA's Senior Vice President of Business Development. CIMA develops products based primarily upon its proprietary OraSolv(R) technology for marketing by multinational pharmaceutical companies. OraSolv(R) is a patented oral dosage form A dosage form is the physical form of a dose of medication, such as a capsule or injection. The route of administration is dependent on the dosage form of a given drug. which incorporates microencapsulated microencapsulated Therapeutics adjective Surrounded by a thin layer of biodegradable substance–eg, a microsphere, as a means of protecting a drug or vaccine antigen from rapid breakdown, or of enhancing antigenic absorption and immune response thereto drug ingredients into a tablet that dissolves quickly in the mouth without chewing or water and which effectively masks the taste of the medication. "Completing our manufacturing facility represents a major milestone for CIMA LABS as we continue to progress toward our strategic objectives. We now have the established capability to meet our anticipated production needs," commented Randall J. Wall, Chairman and Chief Executive Officer of CIMA LABS INC. The 75,000 square foot, leased facility currently has one production line with an initial capacity of 400 million tablets per year. This facility has been designed to be expandable to six production lines to achieve a maximum capacity of 2.4 billion tablets per year. The production facility is located in Eden Prairie, Minnesota The creator of this article, or someone who has substantially contributed to it, may have a conflict of interest regarding its subject matter. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. , and also functions as CIMA's corporate headquarters. Mr. Khattar, 33, had been with Merck & Co., Inc. since 1981, where he last served as Director of Marketing and Business Development and had primary responsibility for licensing and supply agreements. While at Merck, Mr. Khattar managed the switch from prescription to over-the-counter status of several drugs, including Pepcid(R) AC, the OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). version of Pepcid, Merck's anti-ulcer product. CIMA has a License and Supply Agreement with Merck for the development of Pepcid(R) AC using CIMA's AutoLution(R) technology to be marketed internationally. Mr. Khattar has also held marketing positions with Ciba-Geigy, International Playtex, Inc., and Eastman Kodak Company. Mr. Khattar received his M.B.A. in 1985 from the Wharton School of the University of Pennsylvania The Wharton School is the business school of University of Pennsylvania in Philadelphia, Pennsylvania. It was established in 1881 through a donation of Joseph Wharton, making it the world’s oldest business school. and also holds a bachelor's degree in business administration from American University of Beirut American University of Beirut, at Beirut, Lebanon; English language; chartered by New York State in 1866 as Syrian Protestant College, rechartered 1920 as the American Univ. of Beirut. . Wall continued, "We are very pleased to bring Mr. Khattar, with his background in business development and pharmaceutical product marketing, on board. His comprehensive knowledge and experience complements the Company's current management team and enhances our diverse talents and expertise." CIMA is a drug delivery company that was founded in 1987 and has been publicly traded since July 1994. CIMA also has a License and Supply agreement with Pfizer Inc. for multiple OTC pharmaceutical products using OraSolv(R); a License and Development Agreement with Glaxo Group Limited for an OraSolv(R) version of Zantac(R), the world's largest selling drug; and a Development and License Option Agreement with Sterling Winthrop, Inc./SmithKline Beecham, plc/Bayer A.G. for analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs and cold/cough/flu, allergy and sinus OraSolv(R) products. CIMA intends to retain product manufacturing rights in connection with the agreements with its corporate partners, but there can be no assurance in this regard. CONTACT: CIMA Labs Inc., Randall J. Wall Chairman of the Board & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. 612/947-8700 or Dewe Rogerson Inc., New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Kate de Santis 212/688-6840 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion